MedTrace Logo

The Rule of Bupivacaine Hydrochloride in Skin Graft Donor Site

NCT06766474 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-01-13

No results posted yet for this study

Summary

Split Thickness Skin Graft is frequently utilized for reconstructing skin loss of various causes. Unfortunately, the donor site of the STSG has an unavoidable, annoying post-operative pain

Conditions

  • Skin Graft Complications
  • Pain Management

Interventions

DRUG

Bupivacain

to our knowledge, this study is the 1st to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus subcutaneous infiltration for postoperative donor site pain control for patients undergoing STSG procedures.

Sponsors & Collaborators

  • Minia University

    lead OTHER

Principal Investigators

  • MOHAMED SABRY, MD · Lecturer of plastic and reconstructive surgery

  • Shadwa Rabea, MD · Assistant professor of anesthesia and Intensive Care

  • Mohab Elsayed, Phd · Assistant lecturer of plastic and reconstructive surgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-10-15
Completion
2024-10-30
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06766474 on ClinicalTrials.gov